Novartis’ Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults

 Novartis’ Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults

Novartis’ Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults

Shots:

  • The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged <25 yrs. with B-cell acute lymphoblastic leukemia (ALL) in Sep,2018
  • The P-II JULIET results; 18mos.@ median relapse-free survival rate 64%; OR 43%; safe and effective
  • Kymriah is a CAR-T (chimeric antigen receptor T cell) therapy and has also received the US FDA approval for patients with relapsed/refractory (R/R) large B-cell lymphomas

Click here to read full press release/ article | Ref: Nice | Image: Wikipedia

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post